BioMarin CEO expects 'substantial' profitability after FDA approval of hemophilia drug

Jim Cramer chats with Jean-Jacques Bienaimé, chairman and CEO of BioMarin, which focuses on therapies to treat rare diseases.
07:11
Thu, Nov 14 20196:56 PM EST